| GTO ID | GTC2196 |
| Trial ID | NCT04105374 |
| Disease | Glioblastoma |
| Altered gene | yCD |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | Toca 511|vocimagene amiretrorepvec |
| Co-treatment | Extended Release Flucytosine|Radiation Therapy|Temozolomide|Therapeutic Conventional Surgery |
| Phase | Phase2|Phase3 |
| Recruitment status | Withdrawn |
| Title | A Phase II/III Randomized, Open-Label Study of Toca 511, A Retroviral Replicating Vector, Combined With Toca FC With Temozolomide and Radiation Followed by Adjuvant Temozolomide and Toca FC Compared to Temozolomide and Radiation Followed by Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma |
| Year | 2019 |
| Country | United States |
| Company sponsor | NRG Oncology |
| Other ID(s) | NRG-BN006|NCI-2019-04562|NRG-BN006|NRG-BN006|U10CA180868 |
| Vector information | |||
|
|||
| Cohort 1 | |||||
|
|||||